The challenge of the next few years will be to learn how to use drugs at the individual level. This will lead to the development of a personalized medicine of NSAIDs. In order to realize this objective, it will be necessary to develop genetic and biochemical markers which might be useful to identify the responders to NSAIDs or who are uniquely susceptible at developing thrombotic or GI events by COX inhibition. This will lead to the development of individual responder approaches. In this context, the use of pharmacogenomics tools together with pharmacoepidemiological methods will open the way to a new era of pharmacovigilance. This will allow to put information out on drug hazard as quickly as possible and to make appropriate decision on risk management. However, the road is still very long and it is necessary for more work to be performed before this knowledge can be applied to daily practice.
Financial & competing interests disclosure
Angel Lanas is a consultant for AstraZeneca, Pfizer, Bayer and Nicox. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Expert Rev Clin Pharmacol. 2011;4(5):605-621. © 2011 Expert Reviews Ltd.
Cite this: Managing the Adverse Effects of Nonsteroidal Anti-inflammatory Drugs - Medscape - Sep 01, 2011.